{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:18:40Z","timestamp":1777119520739,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","award":["Study funding"],"award-info":[{"award-number":["Study funding"]}],"id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","award":["funding for Rapid Service\/Open Access fees"],"award-info":[{"award-number":["funding for Rapid Service\/Open Access fees"]}],"id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","award":["funding for medical writing assistance"],"award-info":[{"award-number":["funding for medical writing assistance"]}],"id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","award":["Funding for medical writing assistance only"],"award-info":[{"award-number":["Funding for medical writing assistance only"]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40120-024-00602-z","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T08:02:14Z","timestamp":1712390534000},"page":"697-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02959177","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02959190","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2678-6956","authenticated-orcid":false,"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Ooba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-1946","authenticated-orcid":false,"given":"Yuka","family":"Tanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-4219","authenticated-orcid":false,"given":"Akichika","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-1296","authenticated-orcid":false,"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"602_CR1","unstructured":"International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9\u2013160."},{"issue":"12","key":"602_CR2","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1177\/0333102419851855","volume":"39","author":"JL Meyers","year":"2019","unstructured":"Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019;39(12):1518\u201334.","journal-title":"Cephalalgia"},{"issue":"1","key":"602_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68.","journal-title":"J Headache Pain"},{"issue":"5","key":"602_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/14740338.2015.1014797","volume":"14","author":"L V\u00e9csei","year":"2015","unstructured":"V\u00e9csei L, Majl\u00e1th Z, Szok D, Cs\u00e1ti A, Tajti J. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14(5):667\u201381.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"602_CR5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1056\/NEJMp048016","volume":"350","author":"PL Durham","year":"2004","unstructured":"Durham PL. CGRP-receptor antagonists\u2013a fresh approach to migraine therapy? N Engl J Med. 2004;350(11):1073\u20135.","journal-title":"N Engl J Med"},{"issue":"9","key":"602_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase\u00a02, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13(9):885\u201392.","journal-title":"Lancet Neurol"},{"issue":"9","key":"602_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080\u20138.","journal-title":"JAMA Neurol"},{"issue":"8","key":"602_CR8","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase\u00a03 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442\u201354.","journal-title":"Cephalalgia"},{"key":"602_CR9","first-page":"1","volume":"3","author":"F Sakai","year":"2020","unstructured":"Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase\u00a02 randomized controlled clinical trial. Cephalalgia Rep. 2020;3:1\u201310.","journal-title":"Cephalalgia Rep"},{"issue":"24","key":"602_CR10","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321.","journal-title":"Neurology"},{"issue":"10","key":"602_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a03b trial. Lancet Neurol. 2020;19(10):814\u201325.","journal-title":"Lancet Neurol"},{"issue":"6","key":"602_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/head.13508","volume":"59","author":"VL Stauffer","year":"2019","unstructured":"Stauffer VL, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK. Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase\u00a03 trials. Headache. 2019;59(6):834\u201347.","journal-title":"Headache"},{"issue":"8","key":"602_CR13","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis E, Affaitati G, Frattale I, et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci. 2021;42(8):3297\u2013303.","journal-title":"Neurol Sci"},{"issue":"5","key":"602_CR14","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/ene.15260","volume":"29","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. 2022;29(5):1505\u201313.","journal-title":"Eur J Neurol"},{"issue":"11","key":"602_CR15","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1007\/s00415-023-11872-2","volume":"270","author":"F Vernieri","year":"2023","unstructured":"Vernieri F, Brunelli N, Guerzoni S, et al. Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study. J Neurol. 2023;270(11):5436\u201348.","journal-title":"J Neurol"},{"issue":"6","key":"602_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2021.1866536","volume":"20","author":"K Hirata","year":"2021","unstructured":"Hirata K, Takeshima T, Sakai F, et al. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf. 2021;20(6):721\u201333.","journal-title":"Expert Opin Drug Saf"},{"key":"602_CR17","unstructured":"Hall MA. Correlation-based feature selection for machine learning [PhD thesis]. Hamilton, New Zealand: The University of Waikato; 1999."},{"issue":"1","key":"602_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45(1):5\u201332.","journal-title":"Mach Learn"},{"key":"602_CR19","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019."},{"issue":"3","key":"602_CR20","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1007\/s12325-021-01632-x","volume":"38","author":"DK Kuruppu","year":"2021","unstructured":"Kuruppu DK, North JM, Kovacik AJ, Dong Y, Pearlman EM, Hutchinson SL. Onset, maintenance, and cessation of effect of galcanezumab for prevention of migraine: a narrative review of three randomized placebo-controlled trials. Adv Ther. 2021;38(3):1614\u201326.","journal-title":"Adv Ther"},{"issue":"8","key":"602_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s10072-012-1249-9","volume":"34","author":"H G\u00fcven","year":"2013","unstructured":"G\u00fcven H, \u00c7illiler AE, \u00c7omo\u011flu SS. Cutaneous allodynia in patients with episodic migraine. Neurol Sci. 2013;34(8):1397\u2013402.","journal-title":"Neurol Sci"},{"issue":"6","key":"602_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1055\/s-0039-1700525","volume":"39","author":"CL Fraser","year":"2019","unstructured":"Fraser CL, Hepschke JL, Jenkins B, Prasad S. Migraine aura: pathophysiology, mimics, and treatment options. Semin Neurol. 2019;39(6):739\u201348.","journal-title":"Semin Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00602-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T07:33:42Z","timestamp":1716968022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00602-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00602-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takao Takeshima received research funding\/collaborative research expenses from Biohaven, Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Lundbeck Japan K.K., and Shionogi & Co., Ltd., and reports personal fees from Amgen K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Takao Takeshima also acted as an advisor to Hedgehog MedTech, Inc. and Sawai Pharmaceutical Co., Ltd. Hikaru Doi acted as an advisor to Amgen K.K. and Otsuka Pharmaceutical Co., Ltd.; reports research funding from AbbVie GK, Allergan, Inc., Amgen K.K., Biohaven, Ltd., Eli Lilly Japan K.K., Lundbeck Japan K.K., Otsuka Pharmaceutical Co., Ltd., and Pfizer Japan Inc.; and received personal fees from Amgen K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Satomi Ooba reports personal fees from Amgen K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Yuka Tanji, Akichika Ozeki, and Mika Komori are employees of Eli Lilly Japan K.K. and are shareholders in Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocols for both trials were reviewed and approved by local ethics review boards, and written informed consent was obtained from all patients before participation. Both studies were conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. A list of the institutional ethics review boards is provided in Table\u00a0.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}